Fixing a ‘market failure’: To develop new antibiotics, upend the incentive structure, experts urge

The superbug Staphylcocus epidermidis is displayed on an agar plate in a lab in Melbourne, Australia. Source: WILLIAM WEST/AFP/Getty Images

LOS ANGELES — Superbugs, and our dwindling arsenal of drugs that can successfully combat them, are a serious public health concern. The private sector, however, is largely unwilling to take on the financial risk of developing new drugs that could help. Those treatments bring little if any profit.

But what if U.S. policymakers upended the incentive structure for developing new therapies? What if, for instance, drug makers were granted additional exclusivity in certain situations?

Increasingly, the idea

Stai leggendo un'anteprima, registrati per continuare a leggere.

Altro da STAT

STAT1 min letti
STAT+: Pharmalittle: Hospitals Grapple With Extra Dose Of Pfizer Vaccine; FDA Panel Meets To Review Moderna Vaccine
With the Covid-19 vaccine in short supply, hospital pharmacists found themselves throwing away one in every six doses of the first vaccines distributed this week in the U.S.
STAT1 min lettiMedical
STAT+: Pharmalittle: U.S. Considers Giving Half-doses Of Moderna Vaccine; Americans May Not Get AstraZeneca Shot Until April
The U.S. government is considering giving some people half the dose of the Moderna Covid-19 vaccine in order to speed vaccinations.
STAT1 min lettiMedical
STAT+: Pharmalittle: Feds Sue Walmart Over Opioid Prescriptions; U.S. Buys More Pfizer Vaccine Doses
According to a 160-page civil complaint, Walmart knew its system for detecting suspicious prescriptions was faulty but did little to address the matter as its network of pharmacies filled millions…